Crispr Theraptc (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $18.57, for a total transaction of $278,550.00. Following the completion of the sale, the insider now directly owns 167,727 shares of the company’s stock, valued at approximately $3,114,690.39. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Crispr Theraptc (NASDAQ:CRSP) traded down 0.43% during midday trading on Friday, reaching $18.34. 60,044 shares of the company’s stock traded hands. Crispr Theraptc has a one year low of $11.63 and a one year high of $25.00. The company has a 50-day moving average of $17.32 and a 200-day moving average of $17.51. The company’s market capitalization is $744.44 million.
Crispr Theraptc (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. Crispr Theraptc’s revenue was up 350.0% compared to the same quarter last year. Equities research analysts anticipate that Crispr Theraptc will post ($2.43) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/insider-selling-crispr-theraptc-crsp-insider-sells-15000-shares-of-stock-updated.html.
A number of equities research analysts have recently issued reports on CRSP shares. Chardan Capital reaffirmed a “buy” rating on shares of Crispr Theraptc in a research note on Monday. SunTrust Banks, Inc. started coverage on shares of Crispr Theraptc in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research note on Tuesday, July 18th. Finally, Cann started coverage on shares of Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating for the company. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Crispr Theraptc presently has an average rating of “Buy” and a consensus price target of $21.92.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. Monashee Investment Management LLC raised its position in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the last quarter. Paulson & CO. Inc. purchased a new position in Crispr Theraptc during the first quarter valued at approximately $1,099,000. Credit Suisse AG purchased a new position in Crispr Theraptc during the first quarter valued at approximately $1,742,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Crispr Theraptc during the first quarter worth about $110,000. 24.08% of the stock is owned by institutional investors.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.